{"transactions":[{"id":1195522,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-03-20T16:32:22.000Z","date":"2025-03-18","kind":"sale","planned":false,"acquired":false,"shares":10203,"price":0.599,"value":6111.597,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 30,624 RSUs."}],"balance_after":120594,"source":{"system":"sec-edgar","filing":"0001610717-25-000083","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071725000083/form4.xml","form_type":"4"}},{"id":1425118,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Performance Stock Units (PSUs)","published_at":"2024-08-22T18:00:30.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001610717-24-000434","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071724000434/form4.xml","form_type":"4"}},{"id":1425117,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-08-22T18:00:30.000Z","date":"2024-08-20","kind":"sale","planned":false,"acquired":false,"shares":4181,"price":1.2291,"value":5138.8671,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 52,916 restricted stock units."}],"balance_after":130797,"source":{"system":"sec-edgar","filing":"0001610717-24-000434","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071724000434/form4.xml","form_type":"4"}},{"id":1425116,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-08-22T18:00:30.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 52,916 restricted stock units."}],"balance_after":134978,"source":{"system":"sec-edgar","filing":"0001610717-24-000434","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071724000434/form4.xml","form_type":"4"}},{"id":1564658,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-03-21T16:41:27.000Z","date":"2024-03-19","kind":"sale","planned":false,"acquired":false,"shares":5268,"price":2.0855,"value":10986.414,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 52,916 restricted stock units."}],"balance_after":117728,"source":{"system":"sec-edgar","filing":"0001610717-24-000179","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071724000179/form4.xml","form_type":"4"}},{"id":1675066,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Performance Stock Units (PSUs)","published_at":"2024-01-19T20:43:27.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001610717-24-000035","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071724000035/form4.xml","form_type":"4"}},{"id":1675065,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-19T20:43:27.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from January 18, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":100000,"derivative":{"exercise_price":1.68,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001610717-24-000035","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071724000035/form4.xml","form_type":"4"}},{"id":1675064,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-01-19T20:43:27.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2025, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 66,875 RSUs."}],"balance_after":122996,"source":{"system":"sec-edgar","filing":"0001610717-24-000035","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071724000035/form4.xml","form_type":"4"}},{"id":1700713,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-12-22T16:11:46.000Z","date":"2023-12-20","kind":"sale","planned":false,"acquired":false,"shares":4077,"price":1.3807,"value":5629.1139,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs previously reported on December 19, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 41,875 restricted stock units."}],"balance_after":97996,"source":{"system":"sec-edgar","filing":"0001610717-23-000420","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071723000420/form4.xml","form_type":"4"}},{"id":1704553,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Performance Stock Units (PSUs)","published_at":"2023-12-19T19:55:19.000Z","date":"2023-12-17","kind":"exercise","planned":false,"acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents partial vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents partial vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."}],"balance_after":11250,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001610717-23-000409","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071723000409/form4.xml","form_type":"4"}},{"id":1704552,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-12-19T19:55:19.000Z","date":"2023-12-17","kind":"exercise","planned":false,"acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents partial vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 41,875 restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 4,560 shares and 5,654 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2023 and November 30, 2023, respectively."}],"balance_after":102073,"source":{"system":"sec-edgar","filing":"0001610717-23-000409","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071723000409/form4.xml","form_type":"4"}},{"id":1774561,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-09-22T19:12:50.000Z","date":"2023-09-22","kind":"sale","planned":false,"acquired":false,"shares":5486,"price":1.3006,"value":7135.0916,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 41,875 restricted stock units."}],"balance_after":80609,"source":{"system":"sec-edgar","filing":"0001610717-23-000296","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071723000296/form4.xml","form_type":"4"}},{"id":1774560,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-09-22T19:12:50.000Z","date":"2023-09-20","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Performance Stock Units (\"PSUs\") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The second milestone vesting condition was determined to be satisfied upon which the remaining 50% of the PSUs vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 41,875 restricted stock units."}],"balance_after":86095,"source":{"system":"sec-edgar","filing":"0001610717-23-000296","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071723000296/form4.xml","form_type":"4"}},{"id":1944246,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-03-20T18:43:32.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":2037,"price":1.979,"value":4031.223,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 41,875 restricted stock units."}],"balance_after":71095,"source":{"system":"sec-edgar","filing":"0001140361-23-012616","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000114036123012616/form4.xml","form_type":"4"}},{"id":2030400,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Performance Stock Units (PSUs)","published_at":"2023-02-06T16:48:00.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001567619-23-001928","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761923001928/doc1.xml","form_type":"4"}},{"id":2030399,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-06T16:48:00.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":75000,"derivative":{"exercise_price":2.59,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001567619-23-001928","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761923001928/doc1.xml","form_type":"4"}},{"id":2030398,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-02-06T16:48:00.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 47,500 RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 4,443 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 30, 2022."}],"balance_after":73132,"source":{"system":"sec-edgar","filing":"0001567619-23-001928","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761923001928/doc1.xml","form_type":"4"}},{"id":2186808,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Performance Stock Units (PSUs)","published_at":"2022-08-12T16:58:40.000Z","date":"2022-08-10","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."}],"balance_after":22500,"derivative":{"underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001567619-22-015863","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761922015863/doc1.xml","form_type":"4"}},{"id":2186807,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-12T16:58:40.000Z","date":"2022-08-10","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":135000,"derivative":{"exercise_price":1.59,"expiration_date":"2032-08-09","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001567619-22-015863","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761922015863/doc1.xml","form_type":"4"}},{"id":2203800,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-07-21T16:10:02.000Z","date":"2022-07-20","kind":"sale","acquired":false,"shares":5602,"price":1.4223,"value":7967.7246,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 22,500 restricted stock units."}],"balance_after":43689,"source":{"system":"sec-edgar","filing":"0001567619-22-014298","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761922014298/doc1.xml","form_type":"4"}},{"id":2203799,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-07-21T16:10:02.000Z","date":"2022-07-19","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Performance Stock Units (\"PSUs\") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 22,500 restricted stock units."}],"balance_after":49291,"source":{"system":"sec-edgar","filing":"0001567619-22-014298","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761922014298/doc1.xml","form_type":"4"}},{"id":2411523,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-04T16:52:43.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":135000,"derivative":{"exercise_price":4.13,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001567619-22-002524","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761922002524/doc1.xml","form_type":"4"}},{"id":2411522,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-02-04T16:52:43.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on March 15 of each year, with the first 1/4th vesting on March 15, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 22,500 RSUs."}],"balance_after":34291,"source":{"system":"sec-edgar","filing":"0001567619-22-002524","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761922002524/doc1.xml","form_type":"4"}},{"id":2534451,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Performance Stock Units (PSUs)","published_at":"2021-10-26T16:29:58.000Z","date":"2021-10-24","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date."}],"balance_after":30000,"derivative":{"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001567619-21-018719","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761921018719/doc1.xml","form_type":"4"}},{"id":2534450,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-26T16:29:58.000Z","date":"2021-10-24","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from October 24, 2021 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":40000,"derivative":{"exercise_price":5.34,"expiration_date":"2031-10-23","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001567619-21-018719","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761921018719/doc1.xml","form_type":"4"}},{"id":2819401,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-02T16:59:33.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 26, 2021 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":125000,"derivative":{"exercise_price":7.85,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001567619-21-005397","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761921005397/doc1.xml","form_type":"4"}},{"id":3262569,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-19T18:39:04.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2020 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":100000,"derivative":{"exercise_price":7.13,"expiration_date":"2030-02-13","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001567619-20-004347","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761920004347/doc1.xml","form_type":"4"}},{"id":3501999,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2019-06-04T16:08:15.000Z","date":"2019-05-31","kind":"grant","acquired":true,"shares":1812,"price":8.211,"value":14878.332,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"1,812 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":11791,"source":{"system":"sec-edgar","filing":"0001567619-19-012671","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761919012671/doc1.xml","form_type":"4"}},{"id":3611403,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2019-03-05T14:57:09.000Z","date":"2019-03-04","kind":"purchase","acquired":true,"shares":9000,"price":10.33,"value":92970.0,"ownership":{"direct":true},"balance_after":9979,"source":{"system":"sec-edgar","filing":"0001567619-19-006113","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761919006113/doc1.xml","form_type":"4"}},{"id":3683676,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-29T18:58:32.000Z","date":"2019-01-25","kind":"grant","acquired":true,"shares":54900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2019 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":54900,"derivative":{"exercise_price":16.85,"expiration_date":"2029-01-24","underlying":"Common Stock","underlying_shares":54900},"source":{"system":"sec-edgar","filing":"0001567619-19-001864","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761919001864/doc1.xml","form_type":"4"}},{"id":3741126,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2018-12-06T13:55:37.000Z","date":"2018-11-30","kind":"grant","acquired":true,"shares":979,"price":11.73,"value":11483.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"979 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":979,"source":{"system":"sec-edgar","filing":"0001567619-18-007414","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000156761918007414/doc1.xml","form_type":"4"}}]}